How HUTCHMED (China) Limited is positioning HMPL-760 against established BTK therapies in lymphoma care
Can HMPL-760 improve outcomes in relapsed DLBCL? Explore how HUTCHMED is advancing next-gen BTK inhibitors in China.
Genentech advances Gazyva toward first approval in primary membranous nephropathy after Phase III win
Discover how Genentech’s Gazyva Phase III data could reshape treatment goals in membranous nephropathy and what regulators and clinicians will watch next.
Medipost raises $140m to fund U.S. Phase III trial of stem cell therapy for knee osteoarthritis
Medipost secures $140M to fund a pivotal U.S. Phase III trial in osteoarthritis. See how this could reshape the future of scalable stem cell therapies.
AusperBio’s AHB‑137 enters final testing phase in HBeAg-negative chronic hepatitis B patients
AusperBio Therapeutics has completed patient enrollment in its Phase III AUSHINE trial evaluating AHB‑137 for the treatment of HBeAg-negative chronic hepatitis B. The randomized, double-blind, multicenter study, launched in China under regulatory clearance from the Center for Drug Evaluation, surpassed its initial enrollment goal with over 570 patients enrolled within five months. AHB‑137 is being […]
Proton therapy delivers survival gain in head and neck cancer: Could this Lancet trial shift payer and policy resistance?
A new phase III clinical trial published in The Lancet has shown that proton therapy significantly improves overall survival and reduces treatment-related toxicities in patients with oropharyngeal cancers compared to traditional photon-based radiation. Conducted across 21 U.S. institutions and led by researchers at the University of Texas MD Anderson Cancer Center, the study is the […]
Can Akeso’s cadonilimab unlock PD-L1-agnostic immunotherapy for gastric cancer patients?
Akeso Inc. has secured clearance from the United States Food and Drug Administration to initiate COMPASSION-37, a global Phase III trial evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, as part of a first-line treatment regimen for HER2-negative, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. The randomized, multicenter trial will compare cadonilimab plus chemotherapy against […]